Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-24-007229
Filing Date
2024-02-20
Accepted
2024-02-20 16:31:11
Documents
64
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1112761
2 ex31-1.htm EX-31.1 18921
3 ex31-2.htm EX-31.2 19039
4 ex32-1.htm EX-32.1 10401
5 audit_001.jpg GRAPHIC 2345
  Complete submission text file 0001493152-24-007229.txt   4465796

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE impb-20231231.xsd EX-101.SCH 32420
7 XBRL CALCULATION FILE impb-20231231_cal.xml EX-101.CAL 53868
8 XBRL DEFINITION FILE impb-20231231_def.xml EX-101.DEF 107852
9 XBRL LABEL FILE impb-20231231_lab.xml EX-101.LAB 278969
10 XBRL PRESENTATION FILE impb-20231231_pre.xml EX-101.PRE 214382
65 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 454832
Mailing Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084
Business Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084 585 232 1500
IMPACT BIOMEDICAL INC. (Filer) CIK: 0001834105 (see all company filings)

EIN.: 853926944 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 333-253037 | Film No.: 24653977
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)